Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...
Deal terms for Vega include $1.25B upfront and up to $750M sales milestones, with expected close in Q3 2026 and a projected $1.25B R&D charge. VGA039 aims to improve hemostasis via Protein S ...
Contributing factors include genetic predisposition, stress, nutritional deficiencies, autoimmune or thyroid disorders, ...
RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...
FDA’s draft guidance allows sponsors to leverage public and platform knowledge for CMC, nonclinical, and clinical support of ...
Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...
On Sunday, Dr. Brian Wolpin of the Dana-Farber Cancer Institute presented data on pancreatic cancer that is moving the field ...
The results of the survey revealed that the growing direct-to-patient approach is having a significant impact on how ...
The 9-0 decision, authored by Justice Ketanji Brown Jackson, overturned a previous lower appellate court ruling that had ...
Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating ...
A wave of expiries will hit high-value assets, including Keytruda, Eliquis, Ibrance, and Trulicity, amplifying revenue ...
Learn how increasing healthcare complexity and specialty medication adoption are reshaping patient access and affordability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results